On Monday, Piper Sandler updated their financial outlook for Blueprint Medicines (NASDAQ:BPMC), increasing the price target ...
In a report released today, Christopher Raymond from Piper Sandler maintained a Hold rating on Blueprint Medicines (BPMC – Research Report), with a price target of $109.00. The company’s shares closed ...
Piper Sandler analyst Christopher Raymond maintained a Hold rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $109.00. The company’s shares closed yesterday at $86 ...
Blueprint Medicines (NASDAQ:BPMC – Free Report) had its price objective boosted by Piper Sandler from $109.00 to $119.00 in a research note published on Monday morning,Benzinga reports. The brokerage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results